Managing chromoblastomycosis with acitretin plus imiquimod: A case report on the improvement of cutaneous lesions and reduction of the treatment time
Carregando...
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
PASSERO, Luiz Felipe Domingues
Citação
JOURNAL OF DERMATOLOGY, v.48, n.10, p.1612-1615, 2021
Resumo
Chromoblastomycosis (CBM) is an infectious disease caused by fungi that is prevalent in tropical and subtropical countries. Besides few therapeutic options, the classical treatment of CBM needs to be administrated for a long period of time, and unfortunately some patients do not show improvement of the lesions. Thus, it becomes urgent to develop new strategies for the treatment of CBM. This work reports a successful treatment, performed with the combination of oral acitretin (50 mg/kg, once a day) plus topical imiquimod (50 mg/g, five times per week) for 5 months in a patient with CBM. A significant improvement of the lesions was observed in the 1st month, and in the 5th a complete regression of lesions was recorded. Changes in the biochemical parameters were not observed. These data suggest that the combination of acitretin and imiquimod may be effective at treating CBM.
Palavras-chave
acitretin, chromoblastomycosis, imiquimod, lesion evolution, treatment
Referências
- Bao FF, 2018, AM J TROP MED HYG, V99, P124, DOI 10.4269/ajtmh.17-0579
- Belda W, 2020, AM J TROP MED HYG, V103, P1852, DOI 10.4269/ajtmh.20-0471
- Belda W, 2020, J DERMATOL, V47, P409, DOI 10.1111/1346-8138.15225
- Cao Z, 2018, MOL MED REP, V17, P7122, DOI 10.3892/mmr.2018.8734
- de Brito AC, 2018, AN BRAS DERMATOL, V93, P495, DOI 10.1590/abd1806-4841.20187321
- Dogra S, 2013, J EUR ACAD DERMATOL, V27, pe305, DOI 10.1111/j.1468-3083.2012.04644.x
- El Hajj R, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006854
- Elkhachine Y, 2018, ANN DERMATOL VENER, V145, P512, DOI 10.1016/j.annder.2018.04.005
- Kak V, 2012, MED CLIN N AM, V96, P455, DOI 10.1016/j.mcna.2012.04.002
- Mayrink W, 2006, REV SOC BRAS MED TRO, V39, P14, DOI 10.1590/S0037-86822006000100003
- Porras-Lopez C, 2019, AN BRAS DERMATOL, V94, P574, DOI 10.1016/j.abd.2019.09.014
- Queiroz-Telles F, 2009, MED MYCOL, V47, P3, DOI 10.1080/13693780802538001
- de Sousa MDT, 2014, CLIN INFECT DIS, V58, P1734, DOI 10.1093/cid/ciu168
- Voiculescu VM, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/8369690